About
Infinity Bio develops proprietary MIPSA technology to profile antibody binding interactions across comprehensive antigen libraries, supporting research in immunology, infectious diseases, autoimmune disorders, allergy, cancer immunotherapy, and biomarker discovery.
Explore Infinity Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.